胆固醇吸收抑制剂的临床应用

Clinical application of cholesterol absorption inhibitor

新型胆固醇吸收抑制剂依哲麦布(ezetimibe,EZ)可显著降低患者的低密度脂蛋白胆固醇(LDL-C),升高高密度脂蛋白胆固醇(HDL-C)水平,不良反应较少。EZ与他汀类药物联合应用,有良好的药物协同效应,可避免大剂量他汀潜在的不良反应。如果患者在单用最佳剂量他汀类治疗的情况下没有达标,那么EZ联合他汀类可以是一种合理的治疗。

Summary： The new cholesterol absorption inhibitor Ezetimibe （EZ） could markedly reduce the LDL-C level and increase the HDL-C level with little adverse effect. EZ combined with statins shows cooperative effect and avoids the latent adverse effect of large dose of statins. Thus this combined therapy is a reasonable choice for the patients whose cholesterol level could not reach the standard after using optimum dose of statins.